AQAdrien Nguyen Quoc

Adrien Nguyen Quoc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adrien Nguyen Quoc has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Polak

    Institut Cochin, and IMAGINE Institute Affiliate Paris France

    4 shared publications
  • Dulanjalee Kariyawasam

    Institut Cochin, and IMAGINE Institute Affiliate Paris France

    3 shared publications
  • Magali Viaud

    Pediatric Endocrinology, Diabetology and Gynecology Department Necker Children's University Hospital, Assistance Publique Hôpitaux de Paris‐APHP, ENDO‐ERN (European Reference Network) Center for Rare Endocrine Diseases Paris France

    3 shared publications
  • Athanasia Stoupa

    Institut Cochin, and IMAGINE Institute Affiliate Paris France

    2 shared publications
  • Caroline Thalassinos

    Pediatric Endocrinology, Diabetology and Gynecology Department Necker Children's University Hospital, Assistance Publique Hôpitaux de Paris‐APHP, ENDO‐ERN (European Reference Network) Center for Rare Endocrine Diseases Paris France

    2 shared publications
  • Graziella Pinto

    Pediatric Endocrinology, Diabetology and Gynecology Department Necker Children's University Hospital, Assistance Publique Hôpitaux de Paris‐APHP, ENDO‐ERN (European Reference Network) Center for Rare Endocrine Diseases Paris France

    2 shared publications

Latest Publications

  • Open Access

    Clinical, Radiologic and Cytologic Predictors of Malignancy in Pediatric Thyroid Nodules: Insights From a 26‐Year Cohort Study

    by Maxime Gest‐Laurent, Adrien Nguyen Quoc, Christine Lefevre, Laura González‐Briceño, Caroline Thalassinos, Isabelle Flechtner, Dulanjalee Kariyawasam, Yamina Dassa, Magali Viaud, Dinane Samara‐Boustani, et al.

    Introduction: Thyroid nodules are less common but more often malignant in pediatric patients than in adults. Our objectives were to study the features of benign vs. malignant thyroid nodules in a large pediatric patient cohort. Methods: Retrospective observational cohort study. Consecutive patients aged 0.01–17.9 years at evaluation between 1997–2023 for thyroid nodules larger than 0.5 cm recruited at the endocrinology department of Necker Children's University hospital in Paris, France, were included. The main outcome measures concerned the benign or malignant nature of the nodules. The diagnostic accuracy of fine‐needle aspiration biopsy (FNAB) was assessed, as well as the treatments used. Results: We studied 153 patients, 112 (73%) of them were female. Mean age at diagnosis was 12.6 years (0.01–17.9). Malignant nodules were identified more rapidly (0.65 years) than benign (1.25 years) lesions ( p = 0.03). The overall malignancy rate was 17% (26/153). Median largest nodule diameter was 13.1 (8–27) mm; diameter was < 10 mm for 23% of malignant nodules. FNAB was performed in 82/153 cases (53.6%) and was associated with larger nodule size ( p < 0.001) and history of radiation exposure. Autoimmune thyroiditis was present in 19% (4/21) of malignant nodules. By univariate analysis, significant predictors of malignancy were radiation exposure ( p = 0.032), calcifications ( p = 0.022), and lymph node involvement ( p = 0.019). None of these variables was substantial by multivariate analysis. Conclusion: Nodule size, ultrasound characteristics, and FNAB findings alone were insufficient to reliably detect malignancy. Increased vigilance is warranted for subcentimeter nodules and those with autoimmune thyroiditis. Close long‐term follow‐up is advised even in cases with benign cytology.

  • Open Access

    From stem cells to organoids in thyroid: Useful tools or a step for cell therapy?

    by Dulanjalee Kariyawasam, Athanasia Stoupa, Adrien Nguyen Quoc, Ines Pimentel Dantas, Michel Polak, Aurore Carré


  • Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring

    by Alfonso Galderisi, Dulanjalee Kariyawasam, Atanasia Stoupa, Adrien Nguyen Quoc, Graziella Pinto, Magali Viaud, Séverine Brabant, Jacques Beltrand, Michel Polak, Dinane Samara-Boustani

    We appreciate the comment from Dr Dubinski and colleagues as it encourages the discussion about the use of continuous glucose monitoring (CGM) in people with congenital adrenal hyperplasia (CAH). While our study remains the first, to the best of our knowledge, to explore the use of CGM in CAH, the publication of Dr Dubinski's paper 10 days after (November 22) our final draft was online (November 11) suggests the growing need for further investigation in this area. We take advantage of this comment to highlight some differences we were unable to discuss since Dr Dubinski's study was not yet available. The median age difference (11 vs 3.1 years) may certainly be associated with a differential daily glucose pattern in the 2 cohorts due to physiological changes of insulin sensitivity that generally anticipate 1-2 years of the pubertal transition. Our 2 manuscripts highlight 3 major gaps of knowledge in the field: (1) the absence of contemporary “healthy” pediatric cohorts that may serve as control groups for CGM-based studies; (2) the lack of consensus on reporting CGM outcomes in this field. To this end, while we adopted glucose ranges accepted for CGM use in pediatric diabetes due to their clinical relevance, Dubinski's and colleagues explore a wide set of glucose ranges whose granularity may not necessarily be clinically justified; (3) we both opted for reporting the data according to the hydrocortisone dosing and both the cohorts were on a 3-time per day dosing regimen. However, Dubinski and colleagues use 4 temporal intervals (6 Am-12 Am/12 Am-6 Pm/6 Pm-12, and Pm/12 Pm-6 Am), while we only use 3 intervals (10 Pm-7 Am/7 Am-4, and Pm/4 Pm-10 Pm) that corresponds to the 3-time per day dosing regimen. The heterogeneity of reporting CGM data must be addressed in the future to allow a broader and more accurate discussion on existing cohorts.

  • GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

    by Adrien Nguyen Quoc, Kévin Beccaria, Laura González Briceño, Graziella Pinto, Dinane Samara-Boustani, Athanasia Stoupa, Jacques Beltrand, Alix Besançon, Caroline Thalassinos, Stéphanie Puget, et al.

    Context: Craniopharyngioma is a benign brain tumor with frequent local recurrence or progression after treatment. GH replacement therapy (GHRT) is prescribed in children with GH deficiency resulting from childhood-onset craniopharyngioma. Objective: To evaluate whether a shorter delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of a new event (progression or recurrence). Methods: Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset patients with craniopharyngiomas treated with recombinant human GH (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (>12-month group) and 44 patients before 12 months (12-month group and in the 12-month group, the 2- and 5-year event-free survivals were respectively 81.5% (95% CI, 61.1-91.9) and 69.4% (95% CI, 47.9-83.4) compared with 72.2% (95% CI, 56.3-83.1) and 69.8% (95% CI, 53.8-81.2) in the <12-month group. The 2- and 5-year event-free survivals were the same in the 6- to 12-month group (72.4%; 95% CI, 52.4-85.1). By log-rank test, the event-free survival was not different between groups (P = .98 and P = .91). The median time for event was not statistically different. In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment. Conclusions: No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.